ADARx Pharmaceuticals Prices Upsized $446.3 Million IPO

Key Facts

ADARx Pharmaceuticals priced its upsized initial public offering of 26.25 million shares at $17.00 per share. GlobeNewswire reported that the company expects to raise approximately $446.3 million in gross proceeds before deducting underwriting discounts and offering expenses.

The company is transitioning to a public entity to fund the clinical development of its late-stage siRNA therapeutics. This listing occurs amid a broader economic backdrop where the Bank of Japan held interest rates at 1.25% on September 18, 2026, and Germany reported a producer price index of 4.6% on the same date.